Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065542 | 0.87 | F2 (0.52) | F2CACNA1BMEN1ALDH1A1MAPT | |
| SCHEMBL10065544 | 0.86 | CXCR4 (0.56) | F2CACNA1BKDM4EGAARAB9A | |
| SCHEMBL10994169 | 0.82 | RAB9A (0.58) | F2CACNA1BKDM4EMEN1ALDH1A1 | |
| SCHEMBL5310163 | 0.78 | MEN1 (0.68) | F2KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL25825577 | 0.75 | F2 (0.54) | F2GAARAB9AROCK2 | |
| SCHEMBL1680443 | 0.75 | CYP1A2 (0.58) | TAAR1LTA4HMEN1KMT2A | |
| SCHEMBL19743630 | 0.74 | APP (0.54) | TAAR1LTA4HKDM4ETHRBROCK2 | |
| SCHEMBL1757487 | 0.73 | HIF1A (0.63) | F2KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL9107098 | 0.73 | TAAR1 (0.70) | TAAR1LTA4HKDM4EROCK2PRKACA | |
| SCHEMBL2065031 | 0.73 | CYP1A2 (0.69) | LTA4HMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396040-B1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET SA (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
| WO-2010092114-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | F2 1990/4885CACNA1B 1409/4885TAAR1 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.